Royalty Pharma (RPRX) Competitors

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Is RPRX or ZTS a better dividend stock?

Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.5%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.4%. Royalty Pharma pays out 50.9% of its earnings in the form of a dividend. Zoetis pays out 34.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years.

Which has more risk and volatility, RPRX or ZTS?

Royalty Pharma has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Which has better earnings and valuation, RPRX or ZTS?

Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.26B	9.13	$858.98M	$1.73	20.49
Zoetis	$9.26B	6.81	$2.49B	$5.81	24.49

Is RPRX or ZTS more profitable?

Royalty Pharma has a net margin of 44.23% compared to Zoetis' net margin of 27.83%. Zoetis' return on equity of 56.90% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	44.23%	25.54%	14.11%
Zoetis	27.83%	56.90%	19.54%

Do insiders and institutionals hold more shares of RPRX or ZTS?

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts rate RPRX or ZTS?

Royalty Pharma presently has a consensus target price of $46.00, suggesting a potential upside of 29.80%. Zoetis has a consensus target price of $196.71, suggesting a potential upside of 38.25%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Zoetis	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

Does the media prefer RPRX or ZTS?

In the previous week, Zoetis had 27 more articles in the media than Royalty Pharma. MarketBeat recorded 40 mentions for Zoetis and 13 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.38 beat Royalty Pharma's score of 0.96 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	31 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zoetis beats Royalty Pharma on 13 of the 19 factors compared between the two stocks.